P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Katja Weisel,Meletios A. Dimopoulos,Kevin W. Song,Philippe Moreau,Antonio Palumbo,Andrew R. Belch,Stephen Schey,Pieter Sonneveld,Lars Sternas,Xin Yu,Ramesh Amatya,Craig J. Gibson,Mohamed H. Zaki,Christian Jacques,Jesús F. San Miguel +14 more
TL;DR: POM + LoDEX offer good clinical outcomes that lead to improved and prolonged HRQoL compared with HiDEX in patients with RRMM and end-stage disease.
Journal ArticleDOI
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages
Antonin Papin,Antonin Papin,Benoit Tessoulin,Celine Bellanger,Celine Bellanger,Anne Moreau,Yannick Le Bris,Hervé Maisonneuve,Philippe Moreau,Cyrille Touzeau,Martine Amiot,Martine Amiot,Catherine Pellat-Deceunynck,Catherine Pellat-Deceunynck,Steven Le Gouill,David Chiron,David Chiron +16 more
TL;DR: The interplay between MCL cells and the associated monocytes/macrophages is focused on and it is suggested that macrophages are a potential target for developing novel therapeutic strategies in MCL.
Journal ArticleDOI
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.
Mehmet Kemal Samur,Stephane Minvielle,Annamaria Gulla,Mariateresa Fulciniti,Alice Cleynen,Anil Aktas Samur,Raphael Szalat,Masood A. Shammas,Florence Magrangeas,Yu-Tzu Tai,Daniel Auclair,Jonathan J Keats,Paul G. Richardson,Michel Attal,Philippe Moreau,Kenneth C. Anderson,Giovanni Parmigiani,Hervé Avet-Loiseau,Nikhil C. Munshi,Nikhil C. Munshi +19 more
TL;DR: The results suggest that lincRNAs have an independent effect on MM outcome and provide a rationale to evaluate its molecular and biological impact.
Journal ArticleDOI
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Xavier Leleu,Tamás Masszi,Nizar J. Bahlis,Luisa Viterbo,Bartrum W Baker,Peter Gimsing,Vladimir Maisnar,Olga Samoilova,Laura Rosiñol,Christian Langer,Kevin W. Song,Tohru Izumi,Charles S. Cleeland,Deborah Berg,Huamao Mark Lin,Yanyan Zhu,Tomas Skacel,Tomas Skacel,Philippe Moreau,Paul G. Richardson +19 more
TL;DR: It is demonstrated that addition of ixazomib to Rd significantly improved efficacy while HRQoL was maintained, reflecting the limited additional toxicity seen with IRd versus placebo‐Rd, and support the feasibility of long‐term IRd administration.
Journal ArticleDOI
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
Linda Bodet,E Ménoret,Géraldine Descamps,Catherine Pellat-Deceunynck,Régis Bataille,S. Le Gouill,Philippe Moreau,Martine Amiot,Patricia Gomez-Bougie +8 more
TL;DR: Results suggest that Bik has a role in both, apoptosis induction and sensitivity to oxidative stress in myeloma cells, and small BH3 mimetic molecules should be considered for further apoptosis-based therapy in myELoma cells expressing endogenous Bik/Bcl-2 complexes.